Li et al. reported that BATF2 expression in prostate cancer was significantly associated with clinicopathological features such as serum PSA levels, clinical stage, and distant metastasis, which could be a critical player in the recurrence and progression of prostate cancer [26]. Here, BATF2 is linked to prostate carcinoma.